Successes and Challenges with Chimeric Antigen Receptor T-Cell Therapy

This activity consists of recorded presentations from the "12th Annual Medical Director/Physician Leadership Forum" held in Las Vegas, NV on JUNE 13, 2018.

CAR T-cell therapy has the potential to revolutionize cancer treatment. It is expected to expand quickly, with nearly 200 clinical trials ongoing, 50 of which were added in 2016 alone. While the majority of CAR T-cell therapy studies involve B-cell malignancies, this treatment is being investigated in solid tumors as well.

CAR T-cell therapy has been shown to be highly effective against relapsed/refractory (R/R) malignancies; however, serious toxicities present an important treatment challenge. These toxicities, along with the logistical requirements that are needed for CAR T-cell therapy to be adopted in clinical practice, will be reviewed during this activity, as well as approved and emerging CAR T-cell therapies.

Learning objectives
At the end of this educational activity, participants should be able to:

  • State the currently available and emerging CAR T-cell therapies for R/R malignancies.
  • Describe the serious and common toxicities associated with CAR T-cell therapy and strategies for their management.
  • Outline the infrastructure requirements and team competencies required for implementing CAR T-cell therapy in clinical practice and potential barriers against doing so.
  • Discuss potential future directions of CAR T-cell therapy.

Presenter
Faculty PhotoStephen J. Forman, MD
Associate Director for Clinical Sciences,
Director, Clinical Research
Department of Cancer Immunotherapeutics & Tumor Immunology
Beckman Research Institute of City of Hope
Chair, Department of Hematology & Hematopoietic Cell Transplantation
City of Hope
Duarte, CA

Activity planners
Sarah Chart, RN
Senior Director
OptumHealth Education
Eden Prairie, MN

Rebecca Gleason, RN, CCM
Activity Manager
OptumHealth Education
Eden Prairie, MN


Tina Rydland, PharmD
Crystal Clear Rx
Denver, CO

Crystal Wong, MD
President
Propoint Medical Writing
Wexford, PA

Disclosures of relevant financial relationships
In accordance with the ACCME Standards for Commercial SupportSM, OptumHealth Education (OHE) requires all those involved in the development of activity content to disclose their relevant financial relationships. An individual has a relevant financial relationship if such person (or his/her spouse/partner) has a financial relationship in any amount occurring in the last 12 months with a commercial interest whose products or services relate to the activity content. OHE ensures that the content is independent of commercial bias.
Ms. Chart and Ms. Gleason have indicated that they are employees of and own stock in UnitedHealth Group.
Dr. Wong has indicated that she has received grant/research support from MyoKardia.
Dr. Forman has indicated that he has received grant/research support and owns stocks and other ownership interests in Mustang Bio.
The remaining activity faculty or planners have no financial relationships to disclose.

Method of participation
There are no fees for participating in or receiving credit for this activity.
For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

Participants will receive a certificate upon successful completion of the activity, which includes the following:

  • Completing the entire activity
  • Completing the pre- and post-activity assessments, activity evaluation and application for certificate of credit

You must be logged into your account to participate in this activity. Get started by clicking "Begin" and viewing the "CE Info"; then follow the prompts at the bottom of the screen. At the end of the activity, you will be able to view, save or print your certificate of participation. The Area of Practice you indicated in your profile corresponds with your certificate type. A complete listing of all of your activities can be found under "My Account," "My Activities."

Method for calculating CE credit
CE credit was calculated by the complexity of content.

Accreditation Statement
Joint Accreditation LogoIn support of improving patient care, OptumHealth Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the health care team.

Credit Designation Statements
Nurses
The participant will be awarded up to 1.00 contact hour(s) of credit for attendance and completion of supplemental materials.

Nurse practitioners
The American Academy of Nurse Practitioners Certification Program (AANPCP) accepts credit from organizations accredited by the ACCME and ANCC.

Pharmacists/Pharmacy technicians
This activity is approved for 1.00 contact hour(s) ([0.10] CEU) in states that recognize ACPE.
Attending the full program will earn 1.00 contact hour(s).
Unique Activity Number(s): JA0007123-0000-18-122-H01-P/T

Physicians
OptumHealth Education designates this enduring activity for a maximum of 1.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

PAs
The American Academy of Physician Assistants (AAPA) accepts credit from organizations accredited by the ACCME.

Case managers
The Commission for Case Manager Certification has approved this program for a maximum of 1.00 clock hour(s) for Certified Case Managers (CCM).

Attendance
A certificate of attendance will be provided to learners upon completion of activity requirements, enabling participants to register with licensing boards or associations that have not been preapproved for credits. To apply for credit types not listed above, participants should use the procedure established by the specific organization with which they wish to obtain credit.

Provided by
This activity is provided by OptumHealth Education.

Commercial support
There was no commercial support received for this activity.

Hardware/Software requirements
To view this activity, you will need Internet Explorer 7.0+ or Firefox 3.0+ with Windows Media Player 9+, RealPlayer 12+ or Adobe Flash Player 9+. Be sure to disable any pop-up blocking software prior to beginning this activity.

Target Audience

This activity is designed to meet the educational needs of case managers, nurses, pharmacists, pharmacy technicians, physicians and other health care professionals (HCPs) who have an interest in Chimeric Antigen Receptor (CAR) T-Cell Therapy.

Activity summary
Available credit: 
  • 1.00 ACPE - Pharmacists
  • 1.00 ACPE - Pharmacy Technicians
  • 1.00 AMA - Physicians
  • 1.00 ANCC - Nurses
  • 1.00 Attendance - General Attendance
  • 1.00 CCMC - General - Case Managers
Activity opens: 
08/26/2018
Activity expires: 
08/26/2020
Rating: 
0

Available Credit

  • 1.00 ACPE - Pharmacists
  • 1.00 ACPE - Pharmacy Technicians
  • 1.00 AMA - Physicians
  • 1.00 ANCC - Nurses
  • 1.00 Attendance - General Attendance
  • 1.00 CCMC - General - Case Managers
Please log in to register.